Kyowa Kirin brings global reach to Kura’s menin program via licensing deal

With a pivotal readout looming in early 2025, Kura has tapped Kyowa Kirin as a global partner for its menin inhibitor for acute myelogenous leukemia, adding $330 million up front to its balance sheet with the potential for more near-term milestones to follow.

Kura Oncology Inc. (NASDAQ:KURA) expects data within the next several weeks from the registrational Phase II portion of its KOMET-1 trial of zeftomenib, evaluating the candidate in patients with relapsed or refractory NPM1-mutant AML. Ahead of that readout, Kyowa Kirin Co. Ltd. (Tokyo:4151) has acquired all ex-U.S. commercialization rights to the program, as well as a 50-50 profit share and co-development rights inside the U.S...